FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      
           
This page is updated frequently with new Mammal-related patent applications. Subscribe to the Mammal RSS feed to automatically get the update: related Mammal RSS feeds. RSS updates for this page: Mammal RSS RSS


Date/App# patent app List of recent Mammal-related patents
08/21/14
20140237630
 Screening method patent thumbnailnew patent Screening method
The present invention provides a method of screening a mammal for the onset or predisposition to the onset of a neuropsychiatric disorder. More particularly, the present invention provides a method of screening a mammal for the onset or predisposition to the onset of schizophrenia by screening for a decrease in the functional level of protein 14-3-3ζ.
08/21/14
20140235924
 Method of radiotherapy patent thumbnailnew patent Method of radiotherapy
The invention provides a method for the treatment of soft tissue disease in a mammalian subject (preferably a human or canine subject), said method comprising administering to said subject a therapeutically effective quantity of a soft tissue targeting complex of thorium-227 and a complexing agent, wherein said quantity is such that an acceptably non-myelotoxic quantity of radium-223 is generated in vivo by nuclear decay of the administered thorium-227.. .
08/21/14
20140235735
 Protein damage in aging and age-related diseases patent thumbnailnew patent Protein damage in aging and age-related diseases
The process of aging and the development of age-related diseases are related to the emerging phenotypes of increasingly damaged and progressively malfunctioning proteomes. The present invention provides methods of preventing aging and age-related diseases in mammals by assessment of protein-specific oxidative damage.
08/21/14
20140235688
 Treatment of external parasites by oral administration of parasiticidal agents patent thumbnailnew patent Treatment of external parasites by oral administration of parasiticidal agents
Pharmaceutically acceptable compositions of fipronil for oral delivery to mammals and methods for use of the compositions to control external parasites, such as fleas and ticks.. .
08/21/14
20140235681
 Combination therapy for glaucoma patent thumbnailnew patent Combination therapy for glaucoma
Disclosed herein is method of treating glaucoma or ocular hypertension comprising administering a prostaglandin agonist and a second therapeutically active agent to a mammal in need thereof, wherein said second therapeutically active agent is selected from: β-blockers, adrenergic agonists, non-selective adrenergic agonists, α2-selective adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, direct acting cholinergic agonists, chlolinesterase inhibitors, glutamate antagonists, ca2+ channel blockers, prostamides, prostaglandins, cannabinoids, and combinations thereof. Compositions and medicaments containing a combination of these two active agents are also disclosed..
08/21/14
20140235649
 Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function patent thumbnailnew patent Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function
A method of treating a mammalian subject afflicted with a disease characterized by a loss of protein function caused by a genetic abnormality associated with the disease comprising administering to the subject a therapeutically effective amount of a protein phosphatase 2a inhibitor or a histone deacetylase inhibitor.. .
08/21/14
20140235619
 Agents and methods for treating ischemic and other diseases patent thumbnailnew patent Agents and methods for treating ischemic and other diseases
This invention relates to methods of screening for modulators of mammalian cell injury cause by trpm7 gene and protein activity, compounds that modulate trpm7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of trpm7 gene and protein activity.. .
08/21/14
20140235601
 Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males patent thumbnailnew patent Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
The use of an aromatase blocker or an estrogen blocker is described in a method for increasing spermatogenesis and seritolli cell function, and/or improving leydig cell function, in order to to increase endogenous testosterone levels in a male mammal. The levels of active materials used are significantly lower than the levels of these materials used to treat female estrogen sensitive tumors..
08/21/14
20140235564
 Methods for treating neural cell swelling patent thumbnailnew patent Methods for treating neural cell swelling
A composition comprising a novel ca2+-activated, [atp]i-sensitive nonspecific cation (ncca-atp) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [ca]i.
08/21/14
20140235554
 Ophthalmic formulation derived from silk protein patent thumbnailnew patent Ophthalmic formulation derived from silk protein
An ophthalmic composition is described for the treatment of dry eye syndrome in a human or mammal. The composition comprises an aqueous solution including an effective amount of silk protein.
08/21/14
20140235544
new patent Disease treatment via antimicrobial peptides or their inhibitors
The invention provides methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (amp) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. The invention also provides specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous amps or that compete with pro-inflammatory agents or fragments of amps on cognate receptors without inducing disease..
08/21/14
20140235529
new patent Aromatic-cationic peptides and methods for using same
The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of arvd, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis.
08/21/14
20140234966
new patent Albumin formulation and use
The invention relates to a new formulation of albumin, a method for producing the albumin formulation and to uses of the albumin formulation, for example in cell culture such as mammalian cell culture and particularly in stem cell culture.. .
08/21/14
20140234965
new patent Triazine derivatives as differentiation catalysts
A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (i), wherein x is independently —nr4— or —o—, r4 is hydrogen or c1-6-alkyl; r1 is hydroxy, c1-6-alkyl, c1-6-alkoxy, carboxy, c1-6-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, c1-6-alkylamino, or di-c1-6-alkylamino, the c1-6-alkyl or -alkoxy residue being optionally substituted with one or more r5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; r2 is hydrogen, aryl, heteroaryl, or c1-6-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more r1 substituents, and where the c1-6-alkyl is optionally further substituted with one or more r5 substituents; and r3 is selected from hydrogen, halo, nr4r7, or7, sr7, and r7, where the same options apply for r7 as for r2; with the proviso that the compound of formula (i) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.. .
08/21/14
20140234957
new patent Engineered cellular pathways for programmed autoregulation of differentiation
The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type.
08/21/14
20140234905
new patent Cell culture improvements
The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture..
08/21/14
20140234888
new patent Method for improved selection of therapeutic agents
The current invention comprises a method of selection of therapeutic agents for treatment of a particular disease in humans or other mammals in which the ratio of the concentrations of thiol (—sh) and disulfide (—ss—) groups is determined in the blood. The therapeutic agent to be tested may be used to treat a neoplastic, infectious, immunological, inflammatory, or other disorder that involves (but is not limited to) the following physiological systems: respiratory, cardiovascular, genitourinary, gastrointestinal (including the liver and pancreas), neurological, musculoskeletal, immunological, and skin..
08/21/14
20140234863
new patent Immunoassay methods
The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.. .
08/21/14
20140234837
new patent Epigenetic marker for the identification of natural killer cells
The present invention relates to a method, in particular an in vitro method for identifying a subgroup of natural killer cells of a mammal, preferably cd3−, non t-lymphocyte derived nk cells, which often express the surface proteins cd56 and/or cd16, comprising analyzing the accessibility of the genomic dna for osbpl, such as osbpl5, to bisulfite conversion and/or the methylation status of at least one cpg position in the genes for osbpl, such as osbpl5, in particular in their upstream and/or downstream regulatory regions, the promoter, introns, exons and introns exon borders and other conserved regions of said genes, wherein an increase of the accessibility of the genomic dna and/or a demethylation in the sample as analyzed is indicative for said subgroup of nk cells. The analyses according to the invention can identify cd56+ cells and distinguish them from all other cells such as, for example, either cd56− and/or cd56 bright cells.
08/21/14
20140234407
new patent Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day.
08/21/14
20140234400
new patent Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells
A method of preferentially delivering an active agent to an immune cell, such as a myeloid progenitor cell, a dendritic cell, a monocyte, a macrophage or a t-lymphocyte, or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug complex to the subject. The lipid-drug complex is comprised of an active agent, such as a drug, and an outer surface with a targeting ligand that binds a marker on the surface of the immune cell or other cell type that is infected with or susceptible to infection with an infectious agent.
08/21/14
20140234398
new patent Dissolution of arterial plaque
Some embodiments of the present invention provide pharmaceutical formulations, for treating atherosclerosis in a mammal, including a bile acid and/or a terpene atherosclerotic plaque emulsifier. Some embodiments provide methods for administering such pharmaceutical formulations.
08/21/14
20140234378
new patent Lobster hemolymph as a utility for treatment of mammalian tissue lesions
The invention is crustacean hemolymph as a utility for the pharmaceutical and/or cosmetic treatment of viral and other neoplastic or pre-neoplastic mammalian tissue lesions. The method comprises topically administering to mammalian tissue a formula that is made from lobster hemolymph—neat; or lobster hemolymph extracts; or lobster hemolyph in combination with certain carriers, binders; or as an adjuvant.
08/21/14
20140234361
new patent Novel expression vectors and uses thereof
A method for treating an hiv disease in a subject in need of said treatment, comprising administering to the subject a therapeutically effective amount of a dna vaccine comprising an expression vector and a pharmaceutically acceptable excipient, where the expression vector comprises: (a) a heterologous promoter operatively linked to a dna sequence encoding a nuclear-anchoring protein, where the nuclear-anchoring protein comprises: (i) a dna binding domain which binds to a specific dna binding sequence, and (ii) a functional domain of the bovine papilloma virus type 1 e2 protein, where the functional domain binds to a nuclear component; (b) a multimerized dna sequence that forms a binding site for the nuclear anchoring protein; and (c) at least one expression cassette comprising a dna sequence encoding a protein or peptide that stimulates an immune response specific to the protein or peptide; where the expression vector lacks an origin of replication functional in mammalian cells.. .
08/21/14
20140234342
new patent Nkp46-mediated nk cell tuning
The present invention relates to compounds (e.g. Antibodies) that specifically bind and inhibit nkp46.
08/21/14
20140234322
new patent Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal.
08/21/14
20140234299
new patent Therapies for chronic renal failure using one or more integrin antagonists
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists..
08/21/14
20140234297
new patent Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. Dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more fcrs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region..
08/21/14
20140234286
new patent Skeletal muscle regeneration promoter
Provided is a skeletal muscle regeneration promoter for a muscular disorder or myopathy comprising a chondroitinase as an active component, which skeletal muscle regeneration promoter enhances, when administered into a muscular fiber of a mammal with the muscular disorder or myopathy, the regeneration of such a muscular fiber. The above-mentioned chondroitinase degrades chondroitin sulfate that is present at the outer perimeter of the above-mentioned muscular fiber; and thereby inhibition of the regeneration of the muscular fiber by the above-mentioned chondroitin sulfate disappears, which makes it possible to enhance the regeneration and enlargement of such a muscular fiber..
08/21/14
20140234260
new patent Compositions and methods for probiotic recolonization therapies
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of bacteroides, eubacteria, fusobacteria, propionibacteria, lactobacilli, anaerobic cocci, ruminococcus, e.
08/21/14
20140234256
new patent Commensal bacteria as signal mediators within a mammalian host
Genetically engineered cells and microorganisms are provided for preventing or ameliorating diseases through genetically engineered quorum signaling. Therapeutic methods for using the cells and microorganisms to prevent or ameliorate diseases are also provided.
08/21/14
20140234254
new patent Heteroaromatic compounds as pi3 kinase modulators and methods of use
The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (pi3 kinases) and mtor, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans..
08/21/14
20140234250
new patent Methods and compositions for improving appearance and formation of scar tissue
This invention relates to methods and compositions for degrading collagen in mammalian skin, thereby improving the appearance and/or reducing the size of a closed wound, which may be a scar or a keloid and cellulite or other conditions wherein excessive collagen is a problem.. .
08/21/14
20140234249
new patent Methods and compositions for improving appearance and formation of scar tissue
This invention relates to methods and compositions for degrading collagen in mammalian skin, thereby improving the appearance and/or reducing the size of a closed wound, which may be a scar or a keloid and cellulite or other conditions wherein excessive collagen is a problem.. .
08/14/14
20140229115
Methods for diagnosing diseases and evaluating treatments therefor using pet
The present invention relates to methods for determining whether a mammal has a disease, such as diabetes, using pet data analysis techniques. These methods include administering to a mammal a pet-compatible tracer, such as a radioligand specific for a vesicular monoamine transporter 2 (vmat2) receptor, and measuring total functional β-cell capacity (volume) of the mammal's pancreas using pet data analysis techniques.
08/14/14
20140228917
Heat recovering system for light therapy device
The invention relates to a radiation emitting device (1) for application near mammal tissue (2), comprising: a substrate (3) having a front surface (4) and an opposing back surface (5), said substrate accommodating at least one radiation source (6) on said front surface (4). Said at least one radiation source (6) is arranged for applying energy on said mammal tissue (2).
08/14/14
20140228875
Surgical device with integrated visualization and cauterization
Surgical devices with integrated visualization and cauterization are described herein where such devices include an elongate structure having a central lumen and an expandable space-creating structure having at least one expandable leaflet mounted in the vicinity of the distal end and is configured for placement within a mammalian body proximate to a therapeutic target. Also included is a proximal terminal having an actuator mounted in the vicinity of the proximal end and is configured to remain outside of said body and provide an actuation mechanism for actuating the space-creating structure.
08/14/14
20140228818
Urethral catheter tension holding and movement stabilizing devices
This document provides methods and materials involved in holding tension on a urethral catheter and/or stabilizing the movement of a urethral catheter. For example, devices configured to allow a physician to hold tension on a urethral catheter and stabilize movement of a urethral catheter at the urethral meatus in a mammal (e.g., a human) in a non-invasive manner as well as methods for using catheter tension holding and movement stabilizing devices are provided..
08/14/14
20140228790
Wound dressing with a discontinuous contact layer surface
A therapeutic device for promoting the healing of a wound in a mammal is disclosed. An exemplary device comprises a permeable structure having a plurality of depressions formed in a surface thereof.
08/14/14
20140228764
Catheter with variable attachment means
The invention relates to a design for securing tubes, catheters, drains, or other tubular medical devices within the body of a mammal, for example a human, and methods of securing same. The invention includes a first tubular body and at least one second tubular body.
08/14/14
20140228431
Method of treating constipation
Disclosed is a method of manipulating the rate of gastrointestinal transit in a mammalian subject. Also disclosed is the use, in the manufacture of a medicament for the treatment of constipation, of a selective inhibitor of methanogensis, a methanogen-displacing probiotic agent, or a prebiotic agent that inhibits the growth of methanogenic bacteria or promotes the growth of competing non-methanogenic intestinal flora.
08/14/14
20140228361
Aminoquinazoline derivatives and their salts and methods of use
The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling.
08/14/14
20140228319
Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
The present invention relates to pharmaceutically acceptable water soluble salts of aldose reductase inhibitors, 2-(8-oxo-7-((5-trifluromethyl)-1h-benzo[d]imidazol-2-yl)methyl)7,8-dihydropyrazin[2,3-d]pyridazin-5-yl)acetic acid and [4-oxo-(5-trifluoromethyl-benzothaiazol-2-ylmethyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid (also known as zopolrestat), pharmaceutical compositions thereof and methods of treating diabetic complications in mammals comprising administering to mammals these salt and compositions.. .
08/14/14
20140228294
Natriuretic polypeptides with unique pharmacologic profiles
This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity.
08/14/14
20140228287
1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-axanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal
A pharmaceutical composition includes 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs.
08/14/14
20140227703
Epigenetic marker for the identification of il17 positive t cells in complex samples
The present invention relates to a method, in particular an in vitro method for identifying il-17 expressing t cells in a blood and/or tissue sample derived from a mammal, comprising analysing the methylation status of at least one cpg position in the gene il-17a, wherein a demethylation of said at least one cpg position in said sample when compared to an analogous position in a non il-17 blood cell is indicative for a il-17 positive cd4 positive t cell. The analyses according to the invention can identify il-17 positive t cells and distinguish them from all other cells in complex samples, such as, for example, other blood cells.
08/14/14
20140227361
Cross-linked hyaluronic acid and collagen and uses thereof
The present invention discloses a cross-linked hyaluronic acid/collagen formulation which has improved composition for dermal filling and higher persistence than cross-linked collagen or ha alone. Also disclosed are methods for preparing cross-linked hyaluronic acid/collagen formulations and using such for augmenting soft tissues in mammals..
08/14/14
20140227290
Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris
Described is a method for increasing the n-glycosylation site occupancy of a therapeutic glycoprotein produced in recombinant host cells modified as described herein and genetically engineered to express the glycoprotein compared to the n-glycosylation site occupancy of the therapeutic glycoprotein produced in a recombinant host cell not modified as described herein. In particular, the method provides recombinant host cells that overexpress a heterologous single-subunit oligosaccharyltransferase, which in particular embodiments is capable of functionally suppressing the lethal phenotype of a mutation of at least one essential protein of the yeast oligosaccharyltransferase (otase) complex, for example, the leishmania major stt3d protein, in the presence of expression of the host cell genes encoding the endogenous otase complex.
08/14/14
20140227280
Protein complex comprising mcm8 and mcm9 proteins and their use
The composition includes either an isolated protein complex including mcm8 and mcm9 proteins, or nucleic acid molecules coding for the proteins that constitute the complex, or compounds inhibiting the formation and/or the stability, or the activity of the complex, for its use for enhancing or reducing animal, preferably mammal, fertility.. .
08/14/14
20140227272
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains
The present invention relates in essence to a compound which decreases or inhibits the binding of mammalian t-cells to mammalian endothelial cells for use in a method of prophylaxis and/or amelioration and/or treatment of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells in a patient. Methods of treatment of patients having or being at risk of clinical adverse events caused by therapy which comprises re-directing of t-cells against target cells are also contemplated..
08/14/14
20140227269
Therapeutic nuclease compositions and methods
Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.. .
08/14/14
20140227267
Bovine fusion antibodies
Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (cdr3h) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the cdr3h.
08/14/14
20140227261
Use of omega fatty acids for treating disease
Eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), or a salt or an ester thereof, are provided for use in the treatment and/or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. Compositions comprising epa and dha and at least one pharmaceutically acceptable excipient, and kits containing epa, dha and further therapeutic agents are also provided.
08/14/14
20140227254
Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase i (alk1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of bmp9 and/or bmp10, ligands for alk1, may also be used to inhibit angiogenesis in vivo..
08/14/14
20140227235
Cartilage cell treatment comprising collagen, hyaluronic acid derivative, and stem cell derived from mammal umbilical cord
The present invention relates to a medical composite biomaterial. More specifically, the present invention relates to a medical composite biomaterial including collagen and a hyaluronic acid derivative.
08/07/14
20140221490
Methods of treating pain
The presently disclosed subject matter is directed to methods of treating post-operative pain by administering a combination of a lower than minimum approved dose of diclofenac and beta-cyclodextrin. The presently disclosed subject matter is also directed to methods of treating pain in high risk or obese mammals in need of analgesia..
08/07/14
20140221467
Metformin derivatives for treating diabetes and diabetes complications
The invention provides mutual ternary salts of metformin, lipoic acid and acidic amino acids such as aspartic acid and glutamic acid. The invention further provides treatment of prediabetes, diabetes, diabetic complications and/or other conditions in mammals in a method that comprises administering an effective amount of one or more of the foregoing compositions to a mammal in need of such treatment..
08/07/14
20140221459
Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation..
08/07/14
20140221436
Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease
The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations..
08/07/14
20140221405
Platelet adp receptor inhibitors
Novel compounds of formulae (i) to (vii), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylfulfonamide derivatives which are effective platelet adf receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis.
08/07/14
20140221370
Pyrrolopyridines as kinase inhibitors
Compounds of formula (i) are useful for inhibition of chk1 and/or chk2. Methods of using compounds of formula (i) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed..
08/07/14
20140221365
Alkylated piperazine compounds
Alkylated piperazine compounds of formula i are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk kinase, and for treating cancer mediated by btk kinase. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, and treatment of cancer in mammalian cells, or associated pathological conditions, are disclosed..
08/07/14
20140221342
6-substituted phenoxychroman carboxylic acid derivatives
Or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein a1, a2, w, l, g, r7a, r7b, r8, r9 and r10 are as defined herein.. .
08/07/14
20140221279
Regulation of energy metabolism and obesity by modulating a proliferation-inducing ligand (april) or april signaling
Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as b-cell activating factor (baff) and a proliferation-inducing ligand (april), their receptors, and molecules that modulate the interactions between the ligands and receptors..
08/07/14
20140221278
Disease treatment via antimicrobial peptides or their inhibitors
Provided are methods for the treatment of disease and promotion of healing that include providing a therapeutically effective amount of a mammalian antimicrobial peptide (amp) or analog thereof, in particular a cathelicidin or cathelicidin fragment or cathelicidin analog, thereby treating the disease in the subject in need thereof. Also provided are specific analogs or fragments of cathelicidin that function as agonists, as do endogenous cathelicidins, or as either dominant negatives or as inhibitors to endogenous cathelicidin or to other endogenous amps or that compete with pro-inflammatory agents or fragments of amps on cognate receptors without inducing disease..
08/07/14
20140221277
Method for elevating prolactin in mammals
Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels..
08/07/14
20140221252
Detecting neoplasm
This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided..
08/07/14
20140221245
Immunoassay methods
The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used.. .
08/07/14
20140220690
Mammalian genes involved in infection
The present invention relates to nucleic acid sequences and cellular proteins encoded by these sequences that are involved in infection or are otherwise associated with the life cycle of one or more pathogens.. .
08/07/14
20140220629
Novel branchiostoma derived fluorescent proteins
The present invention provides compositions, combinations, methods, sequences and kits for use of novel fluorescent proteins derived from the genus branchiostoma. Specifically, polynucleotide and polypeptide sequences encoding fluorescent proteins isolated from branchiostoma floridae, including harmonized sequences, which permit enhanced expression of the encoded polypeptides in mammalian cells in vivo are provided..
08/07/14
20140220625
Ubiquitin chain assembly
There is provided a method for producing free polyubiquitin chains linked through a single desired lysine residue, comprising the steps of: (a) selecting an e3 ubiquitin ligase enzyme which is homologous to mammalian hect e3 ligases and possesses the desired lysine residue specificity; (b) incubating the e3 enzyme with an e1 ubiquitin activating enzyme, an e2 ubiquitin conjugating enzyme and monomeric ubiquitin; and (c) if undesired linkages are present, removing the undesired linkages by exposure to a dub enzyme having the appropriate specificity.. .
08/07/14
20140220532
Simulation apparatus
A medical simulation model is provided for use in medical training, and having a wall defining a chamber, and having a slit in the wall providing access to the interior of the chamber. A pair of rib-cage members is located within the chamber such that adjacent edges of each member are spaced apart from each other.
08/07/14
20140220116
Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells.
08/07/14
20140220097
Method of implanting a sterile, active agent-coated material and composition made according to same
The present invention relates to a method of implanting a sterile, active agent-coated material comprising contacting a sterile implant with a sterile active agent or active agent solution to form a sterile, active agent-coated implant and, at most a relatively short time after forming the active agent-loaded sterile implant, implanting the active agent-loaded sterile implant into a subject such as a mammal or a human.. .
08/07/14
20140220088
Methods for the production of a cosmetic composition from hatching fluid and uses thereof for improving the cosmetic appearance of skin
The present invention relates to cosmetic compositions obtained or obtainable from salmonidae hatching fluid, methods of producing said compositions and their use in various cosmetic applications to the skin, particularly for reducing or preventing the cosmetic appearance or prevalence of wrinkles, fine lines, hyperpigmentation, laxity, dry skin, scaling and/or transepidermal water loss in skin of a mammalian animal.. .
08/07/14
20140220084
Use of plant cell membrane treatment of obesity
The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition..
08/07/14
20140220074
Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response
Peptides including an amino acid sequence of a fragment of mammalian toll-like receptor-4 (tlr-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a tlr-4 mediated immune response, particularly stimulating tlr-4 mediated immune response, thereby treating infectious diseases and cancer..
08/07/14
20140220073
Immunization compositions and methods
The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or vzv virus.. .
08/07/14
20140220070
Use of plant cell membrane treatment of obesity
The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition..
08/07/14
20140220064
Immunizing composition
The present invention is concerned with an antigenic composition comprising at least one antigen that comprises at least one antigenic epitope or antigenic determinant derived from a protein present in one or both of s. Equi subsp.
08/07/14
20140220048
Apoptotic cell-mediated transfection of mammalian cells with interfering rna
Mammalian host cells for use in a cell-mediated tranfection process, which contain an rnai molecule and an expression vector for a pro-apoptotic protein. The method includes inducing apoptotic cell (ac) death in mammalian cells that contain an rnai molecule capable of downregulating a chosen target gene.
08/07/14
20140220037
Methods for treating reperfusion injuries
The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin. .
08/07/14
20140220004
Compositions and methods for treating pain
Provided herein are compositions containing an antibody or antigen-binding antibody fragment that specifically binds to metallothionein 2 (mt2) protein, and compositions containing an agent that binds to or neutralizes a function of mt2 protein and/or an oligonucleotide that decreases the expression of mt2 mrna in a mammalian cell, and optionally, one or more anti-inflammatory agents and/or analgesics. Also provided are methods of decreasing pain in a mammal that include administering to the mammal an agent that binds to or neutralizes a function of mt2 protein and/or an oligonucleotide that decreases the expression of mt2 mrna in a mammalian cell, in an amount sufficient to decrease the level of extracellular mt2 protein or neutralize a function of extracellular mt2 protein in the mammal, thereby decreasing pain in the mammal..


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4792

3532

2 - 1 - 84